Good everyone, today call. us joining QX Thank and thanks morning, for you, Ken. for our
we perspective, an you achieved detail. quarter. press excellent for very especially great release, quarter strong in we our a earnings I’ll performance. made in financial another revenue more From fruitful delivered and progress strategy our cover later executing As was it and saw innovation, which We growth in
proud deployment strengthen a good Last, achieve With strategic we were continue capital forth to of and momentum opportunities end the positioned to effort teams position. continue our markets to outstanding year. our another and well execute of I’m our strategy behind half share. to us, our on we’re in gain all our and effectively Conditions first those capitalize great put
me Let financial overview begin an highlights. QX of our with
we excellent First, adjusted an increase growth, per EPS XX% delivered achieving share. to $X.XX
QX $X.XX billion, to year-over-year. Our in revenue increased growing X%
margin increased operating adjusted Our the to operating to income points for billion. XX.X% And by adjusted expanded XX our quarter. $X.XX basis X%
will was quarter certain delays provide quarter. caused activity shipments. of resulted the and end processing some on detail, quarter to material, in X-K update referred to not in recent the orders and impact financial and that the to I in outage The our a want The detail. This take quarter provide center a in more data third discuss moment second I to an before days occurred the outage shifting few Before Stephen we filing.
a to resolved. opportunity the get and of work. teams center of this was now at the up It to running want as Our great and our our take intensity of they involvement our I systems issue in keeping to and efforts acknowledge customers are example back culture and front work
in performance the the company quarter, on of position and customers, our across our give our to markets. drive our continue color end gain opportunities growth well end I’ll you our and were of Now team markets with share. overview good the with more context starting Conditions capture an to
this we growth. and market delivered was biotech; Starting of with double-digit quarter and strong very another end pharma
businesses, to customers see across continue with services pharma bioproduction in We strength our all momentum businesses. serving our these and excellent
is Our innovation businesses. unique a value pipelines, help customers across their well enhancing and biopharma partner proposition accelerate us resonating with extremely see while their to strategic productivity as our they them
In low applied, in and industrial delivered growth single-digit we QX.
end market and spectrometry our for this analysis Our demand performance strong products. chemical mass and by was chromatography in driven
Turning to academic flat government, and growth here in quarter. the was
ongoing in conditions more end and we North this by region, strength Looking muted America China in and market saw at Europe.
health Finally single grew the in in we care, in digits low and diagnostics QX.
diagnostics very We seen so in far and clinical strong market continuation market businesses momentum immunodiagnostic channel. demand a in growth this we’ve our saw of also good year. health end our our Conditions in what were care and continued this
about our the markets on to capitalizing So of drive we forward to look continue going second we into customers many the and good the half have serve feel our to and year, opportunities growth.
with strategy, that in our innovative is our you our continuously products; strategy across let We On new me consists our threefold as leveraging to to advancing proposition our businesses. highlights customers. scale made high-growth a in great and many value in and turn emerging of; which note, markets; unique growth QX and know, progress delivering high-impact, developing
our I’ll to best put to the just bring win few Thermo Fisher and examples customers. strategy with our that we’re touch a usual, As success position to build to in continuing demonstrate on our on life how
technology is advances. scientific Beginning a of enabling key reinforce to which our with customers’ across our released products we innovation, excellent number essential our new that businesses leadership,
and a year new-generation conference, an our opportunity important a significant as our range really on our we Spectrometry event great was instruments. was customer us and Society us ASMS for Orbitrap the American you Mass I’ll to always which know, start new reinforce for highlights is with showcased industry workflows. Thermo This leadership. and software introduction a of at milestone hardware, for Most of Scientific
mass combines in analysis allows First, pharmaceutical our This intelligence-driven XXX for data our industry-leading with more and protein identification, translational new quantification technology techniques. high-throughput mass acquisition to applications. use medicine rigorous, new structural Orbitrap and spectrometry Exploris researchers spec system
Tribrid Second, mass our greatly systems, the This biopharmaceutical that high-performance level sensitivity at expands to scientists structures spectrometer access and of system previous quantify enabling Orbitrap with new labs improves instrument and characterize academic provides biomolecules to biological ability generations. government and over to an unprecedented protein Eclipse study and detail. complex a
on this new software customers HR high-resolution a detector electron By first electron integrating electron launched we can In Multi-Attribute control and microscopy speed introduced solution offer also and called to into now Thermo our standardizes the market. new our high-performance that of the accelerate We Thermo characterization automation Method the and Scientific biologics. Scientific biotherapeutic greater development business, workflow and simplifies MicroED, the spec mass which transmission is the we ease-of-use. much diffraction microscopes, quality
launching X leading significantly Turning to offering X strengthened hand-free systems. voice-activated commands operation further the experience. by user Real-Time business, the our as QuantStudio feature and our qPCR improve These such to and genetic PCR smart instruments Pro sciences we cutting-edge technology,
on very great how high-impact the we many and clearly, year unfolds. So track to our examples forward the show look innovation, from momentum long as our building quarter we’re of record that continuing,
leveraging here strategy, in markets, another to our growth we Turning – growth growth high-growth here we of had again element QX. scale strong and our strong the second in had emerging again
growth. quarter we delivered another by highlighted China, was performance where in mid-teens excellent Our
a experience leveraging our to our industry-leading China effectively scale We’re differentiated for customers. create in
of to center access our we to of continue new are serves visited our their our the markets current capabilities technology May, showcases gain quarter. expand Since center Korea our these depth technologies, and and customers a We experts presence to the we with center. to excited in Seoul, our customer grand Korea. opening our for science and and potential This South customers in hundreds about sciences to experience It industry the partner life industry. peers work with in have opened in the hub advance in as
that will We new help build partnerships investment strategic contribute and growth us South significantly to this for are Korea. in opportunities confident
value strategy build of invest enhance position. element third and our we and leading is our our continually customer to on our proposition offering The growth
bring pharma biotech very serving on we end in we have can leadership market, enhancing these Given further the we to the focused the value and are customers.
strategic and with our capabilities this We’re them existing by doing expanding complementing acquisitions.
give combining plan our our a projects, to we’ve manufacturing committed bioproduction announced drive is network pharma bioproduction benefit to our for Missouri. demand. establish expansion single-use examples We we’re meet with our services also example our Center couple a at site our new expand and continued of Louis, capabilities robust recently to of Collaboration leading technologies Bioprocessing capabilities increase We’ve our how customer a To customers growth. technologies. of $XX to services our pharma you million terrific to St. in This
a Bio, very In pleased terms our vector cell and complete leader for viral acquisition Brammer of gene manufacturing we therapies. to in were of acquisitions,
our significantly this on Brammer discussed to viral gene a meeting for detail expands new we As manufacturing. It leverage biosciences, the us fast-growing businesses, market. analyst bioproduction standard our opportunity gives therapy in in and in May, our our capabilities services pharma across and in set some offering Bio vector
to Fisher, in Brammer’s and it our many key to recent and to We welcome sites visits Thermo Florida. nearly XXX new terrific meet Massachusetts of colleagues during was them
integration Thermo the the the business next and Fisher. with taking as is part progress built good making excited they’ve of team about We’re level to the very
support Pharmaceutical in add depression Cork, XXX With intent site employees, a cancers, childhood GlaxoSmithKline. network also site In complex and Cork site Active The that including API our the than our to used to Ingredients, Parkinson’s. capacity or to are APIs, treat we QX, produces announced to demand. acquire Ireland more from diseases, customer will
offering for customers commitment to of our our strengthening and for and these our value shareholders. reinforce All create examples added our
And a our to during We capital our execute you also effectively quick the I’ll give summary activities quarter. of strategy. deployment continue
our we acquisition by capabilities. year. we mentioned, Both to end the forward just site the look Brammer I’ve services of acquisitions As our pharma GSK Bio strengthen closing of completed and the
small offering, We Anatomical This shareholder of that business complex capital overtime a can applications. that will our our for mass analyze create molecules to divestiture we spectrometry QX. help software data we with expands also us identify $X.XX scientists a acquired Last, completed small additional provide of to and to the put variety work billion Pathology transaction HighChem, in business in value.
like that, to our level. XXXX high at With a I’d review guidance
cover on we’re billion and $XX.X the operational X% details. revenue a performance. a Stephen in $XX.X guidance our full new high which both saw to will press result our you billion, revenue our release, guidance to raising the level, on over primarily to range strong earnings As growth would year raising X% we’re XXXX. But based in our of for revenue
our to of we’re year-over-year. $XX.XX, a to per terms range XX% EPS, which to raising represents share, new guidance growth adjusted X% of In $XX.XX
in progress capitalize our our very our and to significant to customers shareholders. our create strong execute the executed and good to terms strategy and So also results. value growth advancing markets our continue well on conditions of for deliver QX, we deployment summarize strategy, we on We our and key effectively financial takeaways from end made capital
With to that, Stephen? now call CFO, over our Stephen hand I’ll the Williamson.
